翰森制药B7-H3靶向药物获EMA优先药物认定
财中社12月16日电翰森制药（03692）发布公告，宣布其B7-H3靶向抗体药物偶联物HS-20093获得欧洲药品管理局（EMA）优先药物（PRIME）认定。该药物由公司与GlaxoSmithKline Intellectual Property (No.4) Limited（GSK）签署的许可协议下开发，GSK获得了全球独占许可（不包括中国内地、香港、澳门及台湾），用于开发、生产及商业化HS-20093。
HS-20093是一种新型的B7-H3靶向抗体药物偶联物，正在进行多项I期、II期及III期临床研究，适应症包括肺癌、肉瘤、头颈癌及其他实体瘤。此外，GSK已于2024年8月20日获得美国食品药品监督管理局（FDA）对GSK227的突破性疗法认定，用于治疗复发或难治性的广泛期小细胞肺癌（ES-SCLC）患者，并于2024年11月1日被中国国家药品监督管理局纳入突破性治疗药物。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10